Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 13/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6139617 | 0.93 | ADRB3 (0.41) | ADRB3ADRB1ADRB2KDM4EALDH1A1 | |
| SCHEMBL6139717 | 0.86 | HSD17B10 (0.40) | ADRB3KDM4EALDH1A1POLBHPGD | |
| SCHEMBL7470047 | 0.83 | ADRB3 (0.45) | ADRB3ADRB1ADRB2CYP3A4CYP2D6 | |
| SCHEMBL6139555 | 0.82 | LMNA (0.42) | ADRB3ADRB1ADRB2KDM4EALDH1A1 | |
| SCHEMBL7458989 | 0.82 | HRH3 (0.43) | ADRB3ADRB1ADRB2CYP3A4CYP2D6 | |
| SCHEMBL6139691 | 0.79 | ALDH1A1 (0.44) | ADRB3ADRB1ADRB2KDM4EALDH1A1 | |
| SCHEMBL6139574 | 0.78 | ALDH1A1 (0.46) | ADRB3ADRB1ADRB2KDM4EALDH1A1 | |
| SCHEMBL7469677 | 0.75 | ADRB1 (0.46) | ADRB3ADRB1ADRB2ALDH1A1POLB | |
| SCHEMBL6139556 | 0.74 | POLB (0.39) | ADRB3ADRB1ADRB2KDM4EALDH1A1 | |
| SCHEMBL6953322 | 0.74 | HRH3 (0.44) | ADRB3ADRB1ADRB2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852736-B2 | Phenoxypropanolamines, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-02-08 | — | — | US | disclosed |
| US-20030105135-A1 | Phenoxypropanolamines, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105135-A1 | Phenoxypropanolamines, preparation and therapeutic use thereof | CNR1, ADRB3, ADRB1 | ADRB3 2/4885ADRB1 3/4885ADRB2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.